Back to Search
Start Over
1102-P: Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report from the ORIGIN Trial
- Source :
- Diabetes. 71
- Publication Year :
- 2022
- Publisher :
- American Diabetes Association, 2022.
-
Abstract
- Diabetes (DM) can be classified into 5 subtypes characterized by distinct progression in dysglycaemia and complications. Using 5 clinical variables, we categorized 7017 participants from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial into 1/auto-immune DM (n=241) , 2/insulin-deficient DM (n=1594) , 3/insulin-resistant DM (n=914) , 4/obesity-related DM (n=1595) , 5/age-related DM (n=2673) .Yet, whether blood biomarkers are associated with these subtypes is unknown. Forward-selection logistic regression models were used to identify biomarkers that were each independent determinant of one cluster versus the others, among 233 selected cardiometabolic proteins measured at baseline. Models were adjusted for age, sex, ethnicity, C-peptide level, diabetes duration. A total of 13, 2, 7 and biomarkers were independent determinants of DM subtypes 2 to 5 respectively (all P Disclosure M.Pigeyre: n/a. H.C.Gerstein: Advisory Panel; Abbott, Eli Lilly and Company, Hanmi Pharm. Co., Ltd., Novo Nordisk, Pfizer Inc., Sanofi, Viatris Inc., Consultant; Kowa Company, Ltd., Other Relationship; DKSH, Eli Lilly and Company, Sanofi, Zuellig Pharma Holdings Pte. Ltd., Research Support; AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. L.Groop: None. S.Hess: Employee; Sanofi. G.Pare: Advisory Panel; Amgen Inc., Bayer AG, Sanofi, Research Support; Bayer AG. Funding NCT00069784 Canadian Institute of Health Research Sanofi
- Subjects :
- Endocrinology, Diabetes and Metabolism
Internal Medicine
Subjects
Details
- ISSN :
- 00121797
- Volume :
- 71
- Database :
- OpenAIRE
- Journal :
- Diabetes
- Accession number :
- edsair.doi...........6b5d1b0228529ed4c599229773693920
- Full Text :
- https://doi.org/10.2337/db22-1102-p